Ligelizumab  (Synonyms: 利戈组单抗; QGE 031; Anti-IGHE Recombinant Antibody)

Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma)^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

IGHE

Ligelizumab 比 Omalizumab (HY-P9950)，能更有效地阻断游离 IgE 与浆细胞样树突状细胞 (pDCs) 上 FcεRI 的结合^[2]。
Ligelizumab 在体外实验中，可恢复经 TLR9-L 刺激的 pDCs 产生 IFN-α 的能力，且效果优于 Omalizumab^[2]。
Ligelizumab 在体外共培养实验中，能像 Omalizumab 一样恢复 pDCs 诱导调节性 T 细胞 (Tregs) 生成的能力^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Ligelizumab (10 μg；腹腔注射；单剂量) 在转人 FcεRIα 的转基因小鼠被动全身过敏反应模型中，可完全保护小鼠免受抗原诱导的全身过敏反应，且相较于 Omalizumab (HY-P9950)，其抑制小鼠腹腔肥大细胞表面 IgE 的效果更显著^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

P01854

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.32 kDa

1322627-61-1

液体

Colorless to light yellow

利戈组单抗；利格利珠单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized IgE Fc Protein, Human can bind Ligelizumab. The EC₅₀ for this effect is 4.31 ng/mL.
• 
  Loaded Ligelizumab on AHC2 biosensor, can bind IgE Protein, Human (HEK293, His, HY-P73907) with an affinity constant of 1.089E-12 M as determined in BLI assay.

• [1]. Gasser P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020 Jan 8;11(1):165.  [Content Brief]

  [2]. Benito-Villalvilla C, et al. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation. Allergy. 2023 Apr;78(4):1060-1072.  [Content Brief]